Urothelial carcinoma (bladder + upper tract) · line 1 · Enfortumab vedotin + pembrolizumab (metastatic urothelial, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-EV-PEMBRO-UROTHELIAL`

ID	`IND-UROTHELIAL-METASTATIC-1L-EV-PEMBRO`
Type	Indication
Status	status not declared
Diseases	`DIS-UROTHELIAL`
Sources	`SRC-NCCN-BLADDER-2025`

Notes

EV-302 paradigm 1L for ALL patients.

Used By

Algorithms

ALGO-UROTHELIAL-METASTATIC-1L - ALGO-UROTHELIAL-METASTATIC-1L

Indication

IND-UROTHELIAL-2L-ERDAFITINIB - IND-UROTHELIAL-2L-ERDAFITINIB

Red flag

RF-UROTHELIAL-EV-CONTRAINDICATED - Enfortumab vedotin (EV) contraindication in urothelial carcinoma — MMAE-related toxicity...